Atacicept: Ph IIb ADDRESS II data

The double-blind, international Phase IIb ADDRESS II trial in 306 SLE patients receiving standard of care (SOC) showed that once-weekly 75 and 150 mg subcutaneous atacicept each missed the primary end...